Nathan Connell: How the 2021 VWD Guidelines Are Actually Changing Real – World Practice
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn about a recent article by Michael Dong et al, published in Haemophilia:
“It’s encouraging to see centers beginning to evaluate how the 2021 von Willebrand disease guidelines are actually changing real-world practice.
This study, published in Haemophilia Journal, examines the impact of the ASH, ISTH, NHF, WFH 2021 guideline diagnostic criteria on patients with ‘low VWF’ in a single – center cohort. The authors, from the Gulf States Hemophilia and Thrombophilia Center in Houston, demonstrated that almost 75 percent of encounters were reclassified from ‘low VWF’ to type 1 VWD when bleeding phenotype was incorporated.
This reclassification led to increased use of VWF therapy and antifibrinolytics, and more than half of patients showed rising VWF levels with age, reinforcing the need for longitudinal reassessment.
Importantly, bleeding phenotypes were broadly similar between ‘low VWF’ and traditional type 1 VWD, supporting the rationale behind the guideline shift.
It is great to see clinical programs moving beyond guideline publication to actually assessing impact within their own patient populations.
That feedback loop is essential if we want guidelines to improve care meaningfully.”
Title: Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients
Authors: Michael Dong, Joanna Larson, Sepideh Saroukhani, Miguel Escobar, Lakshmi Srivaths
Read the Full Article on Haemophilia
Other posts featuring Nathan Connell on Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders